TQB2916 + gemcitabine + nab-paclitaxel

- **TQB2916 + gemcitabine + nab-paclitaxel** is an investigational combination therapy comprising TQB2916 (a humanized IgG2 monoclonal antibody targeting CD40), gemcitabine (a nucleoside analog that inhibits DNA synthesis), and nab-paclitaxel (a nanoparticle albumin-bound form of paclitaxel that stabilizes microtubules)[2][3][4][5][7]. - **TQB2916** acts by agonizing CD40, a co-stimulatory protein found on antigen-presenting cells, activating the immune system, and stimulating anti-tumor T-cell responses and cytotoxic myeloid cells[5][7]. - **Gemcitabine** is incorporated into DNA during replication and causes chain termination, leading to inhibition of tumor cell proliferation. - **Nab-paclitaxel** binds microtubules and prevents their disassembly, disrupting mitosis and promoting apoptosis; the albumin-bound formulation allows improved tumor delivery[2][4]. - The combination is being explored for the treatment of solid tumors, including pancreatic cancer and soft tissue sarcoma[2][3].

Other names

albumin-bound paclitaxelgemcitabine